Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patientsTicagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients

New England Journal of Medicine Published July 26, 2026 Study authors: Shahid Mohammad Maroof, Sajjad Muhammad Hamza, Patel Sanket Kumar Pankajbhai, Tarar Moosa Feroze, Ra… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider ticagrelor over clopidogrel to reduce mortality and MACE in STEMI patients, noting higher revascularization risk.

This meta-analysis evaluates the efficacy and safety of ticagrelor compared to clopidogrel in adult patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI). The analysis included a total sample size of 31,729 patients.

The synthesis indicates that ticagrelor is associated with significantly lower risks for all-cause mortality (OR = 0.64; 95% CI = 0.47-0.88), cardiovascular mortality (OR = 0.68; 95% CI = 0.60-0.93), and major adverse cardiovascular events (OR = 0.71; 95% CI = 0.60-0.84). Additionally, ticagrelor showed lower rates of myocardial infarction (OR = 0.71; 95% CI = 0.61-0.83), stent thrombosis (OR = 0.66; 95% CI = 0.55-0.79), and major bleeding (OR = 0.87; 95% CI = 0.78-0.97). No significant difference was found for stroke risk (OR = 1.16; 95% CI = 0.89-1.52).

A notable limitation is the mixed-design nature of the meta-analysis, which incorporates both randomized controlled trials and observational studies. Furthermore, ticagrelor was associated with a higher risk of target vessel revascularization (OR = 1.30; 95% CI = 1.05-1.61). These findings suggest ticagrelor may offer superior outcomes in several categories but requires consideration regarding revascularization risks.

How this fits prior evidence

This meta-analysis addresses a gap in comparing specific P2Y12 inhibitors post-PCI for STEMI patients. While prior evidence suggests that extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk, this study provides a direct comparison between ticagrelor and clopidogrel. It confirms the potential for improved outcomes in mortality and major adverse cardiovascular events when using ticagrelor over clopidogrel, while identifying a specific increase in target vessel revascularization risk.

Researchers analyzed data from 31,729 adults who experienced a specific type of heart attack (STEMI) and received a procedure called PCI. The study compared two different medications used to prevent blood clots: ticagrelor and clopidogrel.

The findings showed that patients taking ticagrelor had lower rates of all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events compared to those on clopidogrel. Additionally, the data indicated a lower risk of heart attacks, stent thrombosis, and major bleeding for those using ticagrelor. However, there was a higher risk of target vessel revascularization with ticagrelor.

It is important to note that this analysis included both randomized controlled trials and observational studies. Because it combined different types of study designs, the results should be viewed with some caution. While ticagrelor showed several benefits in this large data set, individual risks vary. Patients should speak with their doctors to determine which medication is safest for their specific heart condition.

What this means for you:

Ticagrelor may lower mortality and heart attack risks compared to clopidogrel but carries a higher risk of revascularization.

Common questions

Is ticagrelor safer than clopidogrel for heart patients?

The study found that patients taking ticagrelor had a lower risk of major bleeding compared to those on clopidogrel. However, the analysis also showed a higher risk of target vessel revascularization for those taking ticagrelor. Because this data comes from a mix of trial types, you should talk to your doctor about which medication is best for you.

What are the main benefits of using ticagrelor?

The study showed that ticagrelor was associated with lower rates of all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events. It also showed a lower risk for myocardial infarction (heart attack) and stent thrombosis compared to clopidogrel in the group of 31,729 patients studied.

Does ticagrelor affect stroke risk?

The study found no significant difference in stroke risk between those taking ticagrelor and those taking clopidogrel. The results for stroke were not statistically different, meaning the data did not show one medication was better than the other for preventing strokes.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJul 2026

PMID42499063

View Original Abstract ↓

BACKGROUND: ST-segment elevation myocardial infarction (STEMI) requires primary percutaneous coronary intervention (PCI) and dual antiplatelet therapy with aspirin and a purinergic receptor Y12 inhibitor to reduce thrombotic risks. Ticagrelor, a potent purinergic receptor Y12 inhibitor, offers faster and stronger platelet inhibition than clopidogrel, but evidence on its efficacy and safety in STEMI patients post-PCI is conflicting. This study aims to compare the efficacy and safety of ticagrelor versus clopidogrel in STEMI patients undergoing primary PCI. METHODS: This systematic review and meta-analysis, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, searched PubMed, Embase, ScienceDirect, and ClinicalTrials.gov up to July 2025. Included were randomized controlled trials and observational studies comparing ticagrelor to clopidogrel in adult STEMI patients post-PCI, reporting cardiovascular outcomes. Data were pooled using odds ratios (ORs) with 95% confidence intervals (CIs) via random-effects models. RESULTS: Eight studies (5 randomized controlled trials, 3 observational; n = 31,729) showed ticagrelor significantly reduced all-cause mortality (OR = 0.64, 95% CI = 0.47-0.88; P = .006), cardiovascular mortality (OR = 0.68, 95% CI = 0.60-0.93; P = .01), major adverse cardiovascular events (OR = 0.71, 95% CI = 0.60-0.84; P = .01), myocardial infarction (OR = 0.71, 95% CI = 0.61-0.83; P < .00001), stent thrombosis (OR = 0.66, 95% CI = 0.55-0.79; P < .00001), and major bleeding (OR = 0.87, 95% CI = 0.78-0.97; P = .01), but increased target vessel revascularization (OR = 1.30, 95% CI = 1.05-1.61; P = .02). No significant difference was observed in stroke risk (OR = 1.16, 95% CI = 0.89-1.52; P = .28). CONCLUSION: Ticagrelor outperforms clopidogrel in STEMI post-PCI, reducing key adverse outcomes, though higher target vessel revascularization risk warrants caution.

Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patientsTicagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients

How this fits prior evidence

Common questions

Study Details

Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

People with lupus face higher heart disease risk but genetics show no direct link

Clinical research that matters. Delivered to your inbox.

Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patientsTicagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients

How this fits prior evidence

Common questions

More on ST-Segment Elevation Myocardial Infarction

Study Details

Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

People with lupus face higher heart disease risk but genetics show no direct link

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties